Supplementary Figure 4 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer
Jianzhong Cao(Hunan University of Traditional Chinese Medicine), Qimin Zhan(Peking University), Kelong Ma(Jilin University), Lühua Wang(Nankai University), Wenyang Liu, Guogui Sun(Tangshan People's Hospital), Nan Bi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie He, Xun Zhang(Zaozhuang University), Jie Shen(Soochow University), Hongyu Zhang(Dongguan People’s Hospital), Yongmei Song(Hebei Medical University), Hui Deng(Guangzhou University of Chinese Medicine), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Cheng(Guangzhou Medical University), Ning Lü, Tong Tong(Imperial College London), Jingde Zhu(Shanghai Cancer Institute), Yinghua He, Lei Lv, Jing Fan(Kunming University of Science and Technology), Xiaoying Luo(Shanghai Jiao Tong University)
Cited by 0
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
GADD45 induction of a G <sub>2</sub> /M cell cycle checkpoint
|Proceedings of the National Academy of Sciences|1999|621
PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application
|Drug Delivery|2021|578
Genomic instability in Gadd45a-deficient mice
|Nature Genetics|1999|517